Andreas Evers

Background

About Andreas Evers

An experienced Drug Discovery scientist. Historically working on small molecules and, since 2010, responsible for the rational design and multi-parameter optimization of therapeutic Peptides, proteins and ADCs. Research activities include planning and coordination of activity and physico-chemical characterization studies, update and application of different in silico models and in particular the continuous design of new molecules with the desired properties. Core Competencies and Expertise: • Experience in applying and developing in silico technologies, such as structure-based design, affinity maturation, molecular dynamics, physico-chemical property prediction, library design, in silico ADME and developability, QSAR, immunogenicity, NGS analysis and AI/ML predictions etc. using state-of-the software. In addition, knowledge in programming/scripting (Python). • Experience in applying 3D structural analysis from x-ray, NMR, molecular modeling to visualize, rationalize and optimize not only activity and selectivity, but also physical, chemical, metabolic stability and immunogenicity properties. • Different modalities (peptides with multiple receptor activities, mAbs, VHHs, fusion proteins and ADCs) and therapeutic indications. • Expertise in working in large interdisciplinary and international teams for compound profiling, design and optimization. This includes collaboration with departments from Development to consider developability requirements as additional design aspect in early multi-parameter optimization. Activities include molecular modeling and coordination of experimental profiling of aggregation and stability properties and the (in silico) evaluation of different formulations in early research. Furthermore, expertise in long-term stability and shelf-life prediction for peptides and proteins applying advanced kinetics modeling to provide a robust risk-assessment at entry into development. • Project management for early research CMC activities. • Coordination of academic and commercial scientific collaborations for the evaluation of novel scientific concepts. • Coauthored >20 pharmaceutical compound patents which led to 8 preclinical development candidates. • Co-authored > 30 scientific articles and gave several presentations at international conferences (most recently: EuroPEGS 2017, 2019, 2022, 2023 and 2024, RosettaCon 2023, PhysChem Forum 2019, Festival of Biologics 2022, EMBL Workshop AI/ML for Biologics and Evolutionary Modeling 2022).